RESUMO
BACKGROUND: We investigated the relationship between serum levels of total sialic acid, lipid bound sialic acid and acute pancreatitis in a rat model of a common bile duct ligation induced acute pancreatitis. METHODS: Twenty five Sprague-Dawley male rats weighing 250-300 g were divided into two groups (n=10: control, n=15: experimental). In the control group only a sham laparotomy was performed. In the experimental group, acute pancreatitis was induced by common pancreatobiliary tract ligation. After 36 hours the rats were killed and amylase, serum total sialic acid, lipid bound sialic acid and lipid profiles were measured. Histopathological confirmation of acute pancreatitis was done using hematoxylin and eosin staining. RESULTS: Mean amylase, total sialic acid (TSA) and lipid bound sialic acid (LBSA) measurements in the experimental group were significantly higher than in the control group. There was no significant difference in the lipid profiles between the two groups. CONCLUSION: Increased levels of TSA and LBSA can be useful as specific markers in the diagnosis of acute pancreatitis independent of serum lipid profile.
Assuntos
Amilases/sangue , Lipídeos/sangue , Ácido N-Acetilneuramínico/sangue , Pancreatite/metabolismo , Doença Aguda , Animais , Biomarcadores/sangue , Modelos Animais de Doenças , Masculino , Pancreatite/diagnóstico , Valor Preditivo dos Testes , Ratos , Ratos Sprague-Dawley , Sensibilidade e EspecificidadeRESUMO
Worldwide, breast cancer is the most frequently diagnosed life-threatening cancer in women and the most important cause of cancer-related deaths among women. This disease is on the rise in Turkey. Metabolic syndrome is a cluster of metabolic disturbances including insulin resistance, dyslipidemia, hypertension, abdominal obesity and high blood sugar. Several studies have examined the association of the individual components of the metabolic syndrome with breast cancer. More recent studies have shown it to be an independent risk factor for breast cancer. It has also been associated with poorer prognosis, increased incidence, a more aggressive tumor phenotype. Basic research studies are now in progress to illuminate the molecular pathways and mechanisms that are behind this correlation. Given the fact that all of the components of metabolic syndrome are modifiable risk factors, preventive measures must be established to improve the outcome of breast cancer patients. In this review we set the background by taking into account previous studies which have identified the components of metabolic syndrome individually as breast cancer risk factors. Then we present the latest findings which elaborate possible explanations regarding how metabolic syndrome as a single entity may affect breast cancer risk.
Assuntos
Neoplasias da Mama/etiologia , Síndrome Metabólica/complicações , Feminino , Humanos , PrognósticoAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biomarcadores Tumorais/análise , Neoplasias da Mama/tratamento farmacológico , Neoplasias do Endométrio/tratamento farmacológico , Receptor ErbB-2/análise , Receptores de Estrogênio/análise , Receptores de Progesterona/análise , Neoplasias da Mama/química , Neoplasias da Mama/patologia , Cisplatino/administração & dosagem , Neoplasias do Endométrio/química , Neoplasias do Endométrio/patologia , Feminino , Humanos , Resultado do TratamentoAssuntos
Neoplasias do Colo/patologia , Leucemia Linfocítica Crônica de Células B/patologia , Biomarcadores Tumorais/análise , Biópsia , Neoplasias do Colo/imunologia , Colonoscopia , Feminino , Humanos , Imuno-Histoquímica , Leucemia Linfocítica Crônica de Células B/imunologia , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Valor Preditivo dos Testes , Prognóstico , Tomografia Computadorizada por Raios XAssuntos
Neoplasias da Mama/patologia , Carcinoma Medular/patologia , Adulto , Idoso , Neoplasias da Mama/metabolismo , Carcinoma Medular/metabolismo , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Gradação de Tumores , Estadiamento de Neoplasias , Prognóstico , Receptor ErbB-2/metabolismo , Receptores de Estrogênio/metabolismo , Receptores de Progesterona/metabolismo , Estudos RetrospectivosAssuntos
Antimetabólitos Antineoplásicos/uso terapêutico , Neoplasias dos Ductos Biliares/tratamento farmacológico , Ductos Biliares Intra-Hepáticos , Colangiocarcinoma/tratamento farmacológico , Desoxicitidina/análogos & derivados , Fluoruracila/análogos & derivados , Neoplasias dos Ductos Biliares/mortalidade , Antígeno CA-19-9/sangue , Capecitabina , Colangiocarcinoma/mortalidade , Desoxicitidina/uso terapêutico , Feminino , Fluoruracila/uso terapêutico , Humanos , Pessoa de Meia-Idade , SobreviventesAssuntos
Antineoplásicos Fitogênicos/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Camptotecina/análogos & derivados , Hipocalcemia/induzido quimicamente , Hipopotassemia/induzido quimicamente , Receptor ErbB-2/análise , Neoplasias da Mama/patologia , Camptotecina/efeitos adversos , Feminino , Humanos , Irinotecano , Pessoa de Meia-Idade , Metástase NeoplásicaAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Carcinoma Ductal de Mama/tratamento farmacológico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Carcinoma Ductal de Mama/cirurgia , Quimioterapia Adjuvante , Ciclofosfamida/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Humanos , Metotrexato/administração & dosagem , Metástase NeoplásicaRESUMO
Pulmonary hypertension (PH) is a chronic, progressive debilitating disease and associated with poor prognosis despite the novel numerous treatment options. Beta-blockers constitute a cornerstone in left heart failure treatment; however, we still don't know the role of beta-blockers on PH and they are considered relatively contraindicated in patients with PH because of the possible negative effect on these patients' hemodynamics and exercise capacity. On the other hand, animal models of PH and non-randomized clinical trials have shown that beta-blockers may improve right ventricular function and prevent remodeling in the heart muscle. As it is well-known, right heart function is the main prognostic determinants of the PH. The purpose of this chapter is to present the use of beta-blockers for the treatment of PH, the purported mechanisms of action, previously conducted animal studies and clinical trials.